A peptide’s amino-acid sequence does not always provide its complete functional identity. Ghrelin makes that point particularly clearly: the acyl modification attached to the chain matters to its recognised receptor activity. Yet the distinction should not be reduced to one form doing everything and the other doing nothing. The relevant evidence depends on the endpoint and study design.
The acyl group belongs in the identity
Kojima and colleagues’ 1999 discovery study identified a 28-residue peptide from rat stomach with an n-octanoyl modification on serine 3. That modification was essential for the GH-releasing activity described in the study.Kojima and colleagues — Discovery of acylated ghrelin (opens in a new tab)
The paper also identified a related human sequence differing from the rat peptide at two residues. Thus, both species sequence and acylation state belong in the material description.Kojima and colleagues — Discovery of acylated ghrelin (opens in a new tab)
| Question | What to record |
|---|---|
| Which chain? | Species, sequence and residue count |
| Which modification? | Acyl group, attachment position and whether it is present |
Removing an acyl group is not the same operation as removing amino acids from the chain. Des-acyl, unacylated and non-acylated terminology concerns this chemical distinction; a fragment name addresses a different structural question.
Define what inactive would mean
The original discovery connected the acylated peptide to the growth hormone secretagogue receptor pathway. It distinguished this route from the established GHRH pathway, despite both being relevant to GH release.Kojima and colleagues — Discovery of acylated ghrelin (opens in a new tab)
An activity label must therefore include a target or response. If unacylated ghrelin does not activate the classical receptor in the comparison being discussed, that is narrower than proving that it has no biological effects under any condition.
The converse also matters. An effect attributed to unacylated ghrelin in a different assay does not establish that it acts through the same receptor or reproduces the acylated form’s endocrine profile.
Read the metabolic findings as a developing evidence question
Broglio and colleagues’ 2004 study in six young volunteers reported that co-administered unacylated ghrelin opposed glucose and insulin changes seen with acylated ghrelin, while leaving its measured GH and other neuroendocrine responses intact.Broglio and colleagues — Acylated and non-acylated ghrelin comparison (opens in a new tab)
A 2014 study by Tong and colleagues tested acylated ghrelin, unacylated ghrelin, their combination and saline in 17 healthy participants in random order. It did not find that unacylated ghrelin improved glucose tolerance or beta-cell function, or counteracted the acylated form’s effects in that protocol.Tong and colleagues — Unacylated ghrelin and insulin secretion (opens in a new tab)
The later comparison prevents the earlier result from being presented as a settled universal counterbalancing mechanism. Differences in exposure pattern, glucose challenge and measured outcome need examination before proposing an explanation.
Neither small acute study establishes a long-term treatment effect. Their value here is the direct separation of the two forms and the inclusion of combination and control conditions.
Do not substitute total ghrelin for a defined form
A total-ghrelin result pools whatever molecular forms the assay recognises. To interpret a claim specifically about acylated ghrelin, the measurement must identify that form or provide a justified way to separate it.
For example, an unchanged combined measurement could conceal a change in the relative amounts of two forms. That is a conceptual possibility, not evidence that such a change occurred in a particular dataset.
A useful reading note therefore pairs each intervention name with its measured species: administered acylated peptide, circulating acylated peptide, unacylated peptide or a broader assay signal.
Keeping that distinction visible helps evaluate future studies without converting ghrelin physiology into appetite, body-composition or performance advice. The form, exposure and endpoint must support each conclusion independently.
Sources and further detail
- Kojima and colleagues — Discovery of acylated ghrelin (opens in a new tab)
Original 1999 abstract read for 28-residue identity, serine-3 octanoylation, rat/human distinction and GH-secretagogue pathway. No synthesis or administration instructions.
- Broglio and colleagues — Acylated and non-acylated ghrelin comparison (opens in a new tab)
Complete indexed original 2004 abstract read after direct PubMed access returned no text. Six-person design and metabolic/neuroendocrine distinction retained.
- Tong and colleagues — Unacylated ghrelin and insulin secretion (opens in a new tab)
Original 2014 abstract and indexed methods read. Seventeen-person random-order comparison and absence of the proposed antagonistic metabolic effect retained.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.